viroxime profile

ID Source	ID
PubMed CID	5748733
CHEMBL ID	283403
SCHEMBL ID	3585
MeSH ID	M0076753

Synonym
ar-336
ly-122772
enviroxime
nsc346230
nsc-346230
72301-79-2
enviroxime (usan/inn)
63198-97-0
D04012
1h-benzimidazol-2-amine, 6-[(e)-(hydroxyimino)phenylmethyl]-1-[(1-methylethyl)sulfonyl]-
enviroxima [inn-spanish]
enviroximum [inn-latin]
(e)-2-amino-6-benzoyl-1-(isopropylsulfonyl)benzimidazole oxime
1h-benzimidazol-2-amine, 6-((hydroxyimino)phenylmethyl)-1-((1-methylethyl)sulfonyl)-, (e)-
1h-benzimidazol-2-amine, 6-((e)-(hydroxyimino)phenylmethyl)-1-((1-methylethyl)sulfonyl)-
viroxime component b
nsc 346230
enviroxime [usan:inn]
CHEMBL283403
ly 122772
(ne)-n-[(2-amino-3-propan-2-ylsulfonylbenzimidazol-5-yl)-phenylmethylidene]hydroxylamine
enviroximum
unii-133013l556
enviroxima
133013l556 ,
(z,e)-2-amino-6-benzoyl-1-(isopropylsulfonyl)benzimidazol oxim
ly 122771-72
6-((hydroxyimino)phenylmethyl)-1-((1-methylethyl)sulfonyl)-1h-benzimidazol-2-amine
1h-benzimidazol-2-amine, 6-((hydroxyimino)phenylmethyl)-1-((1-methylethyl)sulfonyl)-
viroxime
ar 336
2-amino-1-(isopropylsulfonyl)-6-benzimidazole phenyl ketone oxime
lilly 122771-72
unii-i5v34wg2be
i5v34wg2be ,
viroxime [usan:inn]
enviroxime [inn]
enviroxime [usan]
enviroxime [mi]
SCHEMBL3585
DTXSID40222628
(1e)-[2-amino-1-[(1-methylethyl)sulfonyl]-1h-benzimidazol-6-yl]phenylmethanone oxime
EX-A7248
2-amino-6-[(e)-alpha-hydroxyiminobenzyl]-1-(isopropylsulfonyl)-1h-benzimidazole
Q27273110
6-[(e)-(hydroxyimino)phenylmethyl]-1-[(1-methylethyl)sulfonyl]- 1h-benzimidazol-2-amine
AKOS040751693

Excerpt	Reference	Relevance
"Enviroxime is a potent antiviral agent with broad spectrum activity in tissue culture against both rhinoviruses and enteroviruses. "	( Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality. Loncharich, R; Spitzer, WA; Tang, J; Victor, F, 1997)	1.27
"Enviroxime is an antienterovirus compound that targets viral protein 3A and/or 3AB and suppresses a step in enterovirus replication by unknown mechanism. "	( Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. Arita, M; Kojima, H; Nagano, T; Okabe, T; Shimizu, H; Wakita, T, 2011)	1.34
"Enviroxime is an antipicornavirus compound that targets host phosphatidylinositol 4-kinase III beta (PI4KB) activity for its antipicornavirus activity. "	( Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. Arita, M; Kojima, H; Nagano, T; Okabe, T; Shimizu, H; Wakita, T, 2013)	1.35
"Enviroxime is an antiviral compound that inhibits the replication of rhinoviruses and enteroviruses. "	( The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. Heinz, BA; Vance, LM, 1995)	1.32

Excerpt	Reference	Relevance
"Enviroxime has been shown to inhibit the replication of rhinoviruses and other enteroviruses in concentrations as low as nanograms per milliliter in in vitro assays but is markedly less effective in clinical trials. "	( Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Gilbert, BE; Knight, V; Six, HR; Wilson, SZ; Wyde, PR, 1988)	1.23

Excerpt	Reference	Relevance
" Free enviroxime and LE were found to have equivalent efficacies against rhinovirus strains 1A and 13 in in vitro assays; however, preparations of LE were 10- to greater than or equal to 50-fold less toxic to tissue culture cells than was free enviroxime."	( Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Gilbert, BE; Knight, V; Six, HR; Wilson, SZ; Wyde, PR, 1988)	0.94

Excerpt	Reference	Relevance
"In an effort to find an orally bioavailable antiviral for the treatment of rhino/enteroviral infections, a series of vinylacetylene benzimidazoles (11a-o, 12, and 18a) was made."	( Antirhino/enteroviral vinylacetylene benzimidazoles: a study of their activity and oral plasma levels in mice. Lee, CC; McKinney, E; Miller, SC; Sattelberg, TR; Spitzer, WA; Tang, JC; Tebbe, MJ; Victor, F, 1997)	0.3

Excerpt	Relevance	Reference
" This allowed a total dosage not much less than might have been given by other routes, but with the advantage that it was evenly deposited over the surface of the infected respiratory tract beginning within seconds of the start of treatment and reached higher concentration in nasal secretions than in serum."	( Chemotherapy of respiratory viruses. Gilbert, BE; Knight, V, 1986)	0.27
" Mortality was seen in all dosing groups of mice treated with either compound, therefore suggesting that short-term inhibition of PI4KIIIβ is deleterious."	( Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo. Bellavance, É; Décor, A; Desmeules, S; Franti, M; Garneau, M; Gauthier, A; Guo, T; Hucke, O; Laberge, MK; Leyssen, P; Lippens, J; Neyts, J; O'Meara, J; Spickler, C; Vaillancourt, FH, 2013)	0.39
" Median effective dose was interpolated from the triplicated experiments and the dose-response curves were generated for each drug-virus combination."	( A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses. Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB, 2020)	0.56

Bioassays (134)

Assay ID	Title	Year	Journal	Article
AID1287135	Antiviral activity against Human coxsackievirus B1 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID86322	Dose required to prevent rhinovirus type 69 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID88374	Antiviral activity against Rhinovirus (RV-16) in HeLa cells using CPE/XTT assay	1997	Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21	Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
AID644560	Antiviral activity against Coxsackievirus B3 Nancy infected in african green monkey Vero cells assessed as inhibition of virus-induced cell death after 3 days by spectrophotometry based MTS/PMS assay	2012	European journal of medicinal chemistry, Mar, Volume: 49	Efficient synthesis and anti-enteroviral activity of 9-arylpurines.
AID644569	Cytotoxicity against Coxsackievirus B3 Nancy infected African green monkey Vero cells assessed as change in cell morphology at EC50 after 3 days by microscopic analysis	2012	European journal of medicinal chemistry, Mar, Volume: 49	Efficient synthesis and anti-enteroviral activity of 9-arylpurines.
AID84728	Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Glu 34 to Val).	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID86671	Percent reduction of plaque formation by rhinovirus type 20 in HeLa cells at conc. 0.00 ug/mL.	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1698659	Antiviral activity against Coxsackie virus B3 HA 201 933 infected in Vero 76 cells assessed as reduction in virus yield by visual inspection method	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID1703103	Antiviral activity against Enterovirus A71 infected in human RD cells assessed as inhibition of viral replication measured by CCK-8 assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: In vitro, in vivo, and combination therapy study.
AID557531	Antiviral activity against Human rhinovirus 72 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1703105	Selectivity index, ratio of CC50 for human RD cells infected with Enterovirus A71 to EC50 for Enterovirus A71 infected in human RD cells	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: In vitro, in vivo, and combination therapy study.
AID86324	Dose required to prevent rhinovirus type 72 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID84733	Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Ile 77 to Val).	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID557534	Antiviral activity against Human rhinovirus 45 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID84726	% survivors was determined against mutants of human rhinovirus 14 by extended cycle replication assay in 1 ug/mL enviroxime by different amino acid substitution	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID644561	Cytotoxicity against African green monkey Vero cells after 3 days by spectrophotometry based MTS/PMS assay	2012	European journal of medicinal chemistry, Mar, Volume: 49	Efficient synthesis and anti-enteroviral activity of 9-arylpurines.
AID86672	Percent reduction of plaque formation by rhinovirus type 20 in HeLa cells at conc. 0.02 ug/mL.	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID86665	Tested in plaque-reduction assay with rhinovirus type 20 at indicated concentration. and the number of plaque formed was reported at conc. 0.17 ug/mL	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1287141	Antiviral activity against Human coxsackievirus B4 infected in african green monkey Vero cells by after 24 to 36 hrs MTS-based CPE reduction assay	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID47193	Compound was evaluated for chemotherapeutic index in CV-1 cells (chemotherapeutic index=50% cytotoxic dose/50% effective dose)	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	Synthesis and antiviral activity of sulfonamidobenzophenone oximes and sulfonamidobenzamides.
AID187079	In vitro hepatic microsomal metabolism in rat	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID88372	Antiviral activity against Poliovirus (PV-1) in HeLa cells using CPE/XTT assay	1997	Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21	Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
AID1698663	Antiviral activity against Enterovirus D68 US/KY/14-18953 infected in RD cells assessed as reduction in virus yield by visual inspection method	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID1287138	Cytotoxicity against human RD cells assessed as reduction in cell viability after 24 to 36 hrs by MTS-based CPE reduction assay	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID557532	Antiviral activity against Human rhinovirus 70 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID200189	In vitro activity against Rhinovirus type 1B by plaque inhibition assay.	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	9-Benzyl-6-(dimethylamino)-9H-purines with antirhinovirus activity.
AID95482	Cellular toxicity in KB cells	2003	Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15	An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.
AID1287137	Antiviral activity against Enterovirus 71 infected in human RD cells after 24 to 36 hrs by MTS-based CPE reduction assay	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID557772	Antiviral activity against Human coxsackievirus B3 harboring wild type nonstructural protein 3A infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1287143	Antiviral activity against Human coxsackievirus B6 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID557529	Antiviral activity against Human rhinovirus 86 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID105851	Cellular toxicity against HRV-1A strain in MRC-5 cells; Not tested	2003	Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15	An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.
AID59918	In vitro hepatic microsomal metabolism in dog	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID1698660	Selectivity index, ratio for CC50 of monkey Vero 76 cells to EC50 for Coxsackie virus B3 HA 201 933 by visual inspection method	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID1698664	Cytotoxicity against human RD cells by microscopic based visual inspection method	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID1287131	Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 24 to 36 hrs by MTS-based CPE reduction assay	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID86673	Percent reduction of plaque formation by rhinovirus type 20 in HeLa cells at conc. 0.04 ug/mL.	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID557775	Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A I54F mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID88711	Dose required to prevent rhinovirus type 3 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID84734	Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Met 54 to Ile)	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID557773	Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A I8T mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID557761	Antiviral activity against Human rhinovirus 2 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID557755	Antiviral activity against Human poliovirus 1 strain Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1703104	Cytotoxicity against human RD cells infected with Enterovirus A71 assessed as reduction in cell viability measured by CCK-8 assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: In vitro, in vivo, and combination therapy study.
AID14287	Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.	1997	Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24	Antirhino/enteroviral vinylacetylene benzimidazoles: a study of their activity and oral plasma levels in mice.
AID84741	% survivors was determined against mutants of human rhinovirus 14 by extended cycle replication assay in 1 ug/mL enviroxime	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID86320	Dose required to prevent rhinovirus type 61 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID47192	Antiviral activity against poliovirus type 1 in CV-1 cells	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	Synthesis and antiviral activity of sulfonamidobenzophenone oximes and sulfonamidobenzamides.
AID89954	In vitro hepatic microsomal metabolism in human	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID86317	Dose required to prevent rhinovirus type 37 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID88709	Dose required to prevent rhinovirus type 16 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID162231	Antiviral activity against polio 1 virus using a plaque-inhibition assay	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	Synthesis and antiviral activity of sulfonamidobenzophenone oximes and sulfonamidobenzamides.
AID84727	Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Asp 28 to Tyr).	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID86663	Tested in plaque-reduction assay with rhinovirus type 20 at indicated concentration. and the number of plaque formed was reported at conc. 0.04 ug/mL	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1876111	Cytotoxicity against human Huh-7 cells	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID557760	Antiviral activity against Human rhinovirus 89 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID88362	Antiviral activity against Coxsackie virus (CoxA21) in HeLa cells using CPE/XTT assay	1997	Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21	Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
AID84731	Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Ile 32 to Val)	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID199693	Antiviral activity was evaluated against rhino virus using PRA assay	2003	Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20	Imidazo[1,2-b]pyridazines, novel nucleus with potent and broad spectrum activity against human picornaviruses: design, synthesis, and biological evaluation.
AID199881	Antiviral activity against rhinovirus 10 using plaque-inhibition assay	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	Synthesis and antiviral activity of sulfonamidobenzophenone oximes and sulfonamidobenzamides.
AID86677	Percent reduction of plaque formation by rhinovirus type 20 in HeLa cells at conc. 0.75 ug/mL.	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID557539	Antiviral activity against Human rhinovirus 14 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID88710	Dose required to prevent rhinovirus type 20 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID557530	Antiviral activity against Human rhinovirus 85 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID86319	Dose required to prevent rhinovirus type 50 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1698662	Selectivity index, ratio for CC50 of monkey Vero 76 cells to EC50 for Coxsackie virus B3 HA 201 933 by neutral red uptake assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID88713	Dose required to prevent rhinovirus type 33 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID84719	inhibitory concentration against mutants of human rhinovirus 14 by standard plague reduction assay by different amino acid substitution	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID557540	Antiviral activity against Human rhinovirus 9 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1698665	Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus D68 US/KY/14-18953 strain	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID84732	Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Ile 42 to Val)	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID557776	Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A H57Y mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID445047	Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by MTS assay	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	9-Arylpurines as a novel class of enterovirus inhibitors.
AID88707	Dose required to prevent rhinovirus type 14 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID86661	Tested in plaque-reduction assay with rhinovirus type 20 at indicated concentration. and the number of plaque formed was reported at conc. 0.00 ug/mL	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID134631	In vitro hepatic microsomal metabolism in mouse	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID88708	Dose required to prevent rhinovirus type 15 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1698661	Antiviral activity against Coxsackie virus B3 HA 201 933 infected in Vero 76 cells assessed as reduction in virus-induced cytopathic effect by neutral red uptake assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID86664	Tested in plaque-reduction assay with rhinovirus type 20 at indicated concentration. and the number of plaque formed was reported at conc. 0.08 ug/mL	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID86321	Dose required to prevent rhinovirus type 65 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1287140	Antiviral activity against Human coxsackievirus B3 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID1698668	Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus D68 US/KY/14-18953 by neutral red uptake assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID86676	Percent reduction of plaque formation by rhinovirus type 20 in HeLa cells at conc. 0.35 ug/mL.	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1287134	Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Enterovirus 71	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID88712	Dose required to prevent rhinovirus type 32 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID644568	Antiviral activity against drug-resistant Coxsackievirus B3 Nancy infected in african green monkey Vero cells assessed as inhibition of virus-induced cell death after 3 days by spectrophotometry based MTS/PMS assay	2012	European journal of medicinal chemistry, Mar, Volume: 49	Efficient synthesis and anti-enteroviral activity of 9-arylpurines.
AID557762	Antiviral activity against Human rhinovirus 29 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID86674	Percent reduction of plaque formation by rhinovirus type 20 in HeLa cells at conc. 0.08 ug/mL.	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID84729	Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Glu 51 to Val)	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID86667	Tested in plaque-reduction assay with rhinovirus type 20 at indicated concentration. and the number of plaque formed was reported at conc. 0.75 ug/mL	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID557537	Antiviral activity against Human rhinovirus 39 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID557538	Antiviral activity against Human rhinovirus 15 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID42136	Antiviral activity against Poliovirus (PV-1) using plaque reduction assay using BSC1 cells	1997	Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21	Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
AID87785	Chemotherapeutic index in Hela cells (chemotherapeutic index=50% cytotoxic dose/50% effective dose)	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	Synthesis and antiviral activity of sulfonamidobenzophenone oximes and sulfonamidobenzamides.
AID88375	Antiviral activity against Rhinovirus (RV-2) in HeLa cells using CPE/XTT assay	1997	Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21	Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
AID557535	Antiviral activity against Human rhinovirus 42 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1703114	Antiviral activity against Enterovirus A71 infected in human RD cells using HEX-labelled RNA as substrate assessed as inhibition of dsRNA unwinding by measuring accumulation of dsRNA at 0.56 uM treated 8 hpi by gel based flourescence assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: In vitro, in vivo, and combination therapy study.
AID87792	Antiviral activity against rhinovirus type 10 in Hela cells	1986	Journal of medicinal chemistry, Mar, Volume: 29, Issue:3	Synthesis and antiviral activity of sulfonamidobenzophenone oximes and sulfonamidobenzamides.
AID557541	Antiviral activity against Human poliovirus 3 strain Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1698669	Antiviral activity against Poliovirus 1 Mahoney infected in monkey Vero 76 cells assessed as reduction in virus yield by visual inspection method	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID1698670	Selectivity index, ratio of CC50 for monkey Vero 76 cells to EC50 for Poliovirus 1 Mahoney	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID1876071	Antiviral activity against HCV	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID557758	Antiviral activity against Human enterovirus 71 (strain BRCR) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID86323	Dose required to prevent rhinovirus type 70 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID84891	Anti-HRV activity against HRV-1A strain; Not tested	2003	Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15	An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.
AID1287132	Antiviral activity against Human enterovirus 71 infected in monkey African green Vero cells by MTS-based CPE reduction assay	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID557757	Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID88373	Antiviral activity against Rhinovirus (RV-14) in HeLa cells using CPE/XTT assay	1997	Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21	Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
AID84743	% survivors was determined against mutants of human rhinovirus 14 by extended cycle replication assay in 1 ug/mL enviroxime by different amino acid substitution by different amino acid substitution	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID84735	Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime. wild type	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID84742	% survivors was determined against mutants of human rhinovirus 14 by extended cycle replication assay in 1 ug/mL enviroxime by different amino acid substitution	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID86318	Dose required to prevent rhinovirus type 48 plaque formation in HeLa cells by 50%ug/mL of agar overlay	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID86666	Tested in plaque-reduction assay with rhinovirus type 20 at indicated concentration. and the number of plaque formed was reported at conc. 0.35 ug/mL	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1698671	Antiviral activity against Poliovirus 1 Mahoney infected in monkey Vero 76 cells assessed as reduction in virus-induced cytopathic effect by neutral red uptake assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID1876042	Antiviral activity against HCV GT1b-genotype assessed as inhibition of viral replication	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID84730	Compound was tested for resistance (survivors(%)) by extended cycle replication assay conducted in 1 ug/mL Enviroxime.(3A amino acid substitution Gly 72 to Ser)	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID1287142	Antiviral activity against Human coxsackievirus B5 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID557536	Antiviral activity against Human rhinovirus 41 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID557774	Antiviral activity against Human coxsackievirus B3 harboring nonstructural protein 3A V45A mutant infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by plaque assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1698672	Selectivity index, ratio of CC50 for monkey Vero 76 cells to EC50 for Poliovirus 1 Mahoney by neutral red uptake assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID445048	Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	9-Arylpurines as a novel class of enterovirus inhibitors.
AID557759	Antiviral activity against Human coxsackievirus A16 (strain G-10) A16 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID86662	Tested in plaque-reduction assay with rhinovirus type 20 at indicated concentration. and the number of plaque formed was reported at conc. 0.02 ug/mL	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID557533	Antiviral activity against Human rhinovirus 63 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID557754	Antiviral activity against Human poliovirus 2 Sabin infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID1698666	Antiviral activity against Enterovirus D68 US/KY/14-18953 strain infected in RD cells assessed as reduction in virus-induced cytopathic effect by neutral red uptake assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
AID93754	Inhibitory concentration required against Human rhinovirus-14 (HRV-14) using plaque reduction assay	1999	Bioorganic & medicinal chemistry letters, May-17, Volume: 9, Issue:10	Short synthesis and anti-rhinoviral activity of imidazo[1,2-a]pyridines: the effect of acyl groups at 3-position.
AID1287139	Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus 71	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID557756	Antiviral activity against Human coxsackievirus A21 (strain Coe) infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.
AID126648	In vitro hepatic microsomal metabolism in monkey	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
AID84908	Anti-HRV activity against HRV-2 strain	2003	Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15	An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.
AID1287136	Antiviral activity against Human coxsackievirus B2 infected in african green monkey Vero cells after 24 to 36 hrs by MTS-based CPE reduction assay	2016	Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5	Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.
AID86675	Percent reduction of plaque formation by rhinovirus type 20 in HeLa cells at conc. 0.17 ug/mL.	1980	Journal of medicinal chemistry, Apr, Volume: 23, Issue:4	Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.
AID1698667	Cytotoxicity against human RD cells by neutral red uptake assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	21 (34.43)	18.7374
1990's	13 (21.31)	18.2507
2000's	8 (13.11)	29.6817
2010's	15 (24.59)	24.3611
2020's	4 (6.56)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	6 (9.84%)	5.53%
Reviews	6 (9.84%)	6.00%
Case Studies	1 (1.64%)	4.05%
Observational	0 (0.00%)	0.25%
Other	48 (78.69%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
pleconaril WIN 63843: structure given in first source	2.78	3	0
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	4.45	1	1	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
bisindolylmaleimide iv [no description available]	2.41	1	0	indoles; maleimides
dibucaine Dibucaine: A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006). cinchocaine : A monocarboxylic acid amide that is the 2-(diethylamino)ethyl amide of 2-butoxyquinoline-4-carboxylic acid. One of the most potent and toxic of the long-acting local anesthetics, its parenteral use was restricted to spinal anesthesia. It is now generally only used (usually as the hydrochloride) in creams and ointments and in suppositories for temporary relief of pain and itching associated with skin and anorectal conditions.	2.25	1	0	aromatic ether; monocarboxylic acid amide; tertiary amino compound	topical anaesthetic
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	2.25	1	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
guanidine Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.	2.69	3	0	carboxamidine; guanidines; one-carbon compound
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	2.41	1	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.41	1	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
norfluoxetine norfluoxetine: metabolite of fluoxetine; RN given refers to parent cpd without isomeric designation	2.25	1	0	(trifluoromethyl)benzenes
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	2.41	1	0	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
rimantadine Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.	4.45	1	1	alkylamine
tyrphostin a9 [no description available]	2.41	1	0	alkylbenzene	geroprotector
2-hydroxybenzylbenzimidazole 2-hydroxybenzylbenzimidazole: RN given refers to cpd without isomeric designation	1.96	1	0
uridine [no description available]	1.98	1	0	uridines	drug metabolite; fundamental metabolite; human metabolite
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	2.1	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
cytidine [no description available]	2.1	1	0	cytidines	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
chloroform Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity.. chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines.	2.37	2	0	chloromethanes; one-carbon compound	carcinogenic agent; central nervous system drug; inhalation anaesthetic; non-polar solvent; refrigerant
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	2.1	1	0	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	1.99	1	0	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	3.26	6	0	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	2.58	2	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	2.08	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	2.25	1	0	diazine; pyrazines	Daphnia magna metabolite
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	4.45	1	1	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
2-benzimidazolylguanidine 2-benzimidazolylguanidine: effects chloride efflux in tissue; RN given refers to parent cpd	1.96	1	0	aminoimidazole
ribavirin Rebetron: Rebetron is tradename	5.61	5	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
arildone [no description available]	3.78	3	0	methoxybenzenes
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	2.25	1	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
3-deazaguanine 3-deazaguanine: structure	2.13	1	0
disoxaril disoxaril: antipicornavirus agent	3.26	6	0	aromatic ether
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	2.08	1	0	cephalosporin	fungal metabolite
pirodavir pirodavir: antipicornavirus agent; structure given in first source	3	4	0
rmi 15731 RMI 15731: structure	2.37	2	0
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.41	1	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	2.41	1	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
4',6-dichloroflavan 4',6-dichloroflavan: antirhinovirus cpd; structure given in first source	9.16	5	0
lestaurtinib [no description available]	2.41	1	0	indolocarbazole
canertinib [no description available]	2.41	1	0	monochlorobenzenes; morpholines; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	2.41	1	0	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
sb 203580 [no description available]	2.41	1	0	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
erlotinib [no description available]	2.41	1	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
ethyl-2-methylthio-4-methyl-5-pyrimidine carboxylate [no description available]	2.41	2	0
sorafenib [no description available]	2.41	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	2.25	1	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
pd 166326 PD 166326: a pyrido(2,3-d)pyrimidine src tyrosine kinase inhibitor	2.41	1	0
purvalanol a 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;	2.41	1	0	purvalanol
favipiravir favipiravir : A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan.	2.25	1	0	hydroxypyrazine; organofluorine compound; primary carboxamide	anticoronaviral agent; antiviral drug; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
2'-c-methylcytidine 2'-C-methylcytidine: structure in first source	2.1	1	0
chalcone trans-chalcone : The trans-isomer of chalcone.	3.98	4	0	chalcone	EC 3.2.1.1 (alpha-amylase) inhibitor
s 1033 [no description available]	2.41	1	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
phenylthiourea Phenylthiourea: Phenylthiourea is a THIOUREA derivative containing a phenyl ring. Depending on their genetic makeup, humans can find it either bitter-tasting or tasteless.. N-phenylthiourea : A member of the class of thioureas that is thiourea in which one of the hydrogens is replaced by a phenyl group. Depending on their genetic makeup, humans find it either very bitter-tasting or tasteless. This unusual property resulted in N-phenylthiourea being used in paternity testing prior to the advent of DNA testing.	2.41	2	0	thioureas	EC 1.14.18.1 (tyrosinase) inhibitor
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol [no description available]	2.41	1	0	substituted aniline
n-phenyl-n'-3-hydroxyphenylthiourea [no description available]	2.41	2	0
rhodanine 2-mercaptothiazolinone: metabolite in urine from persons exposed to CS2; structure	3.06	1	0	thiazolidinone
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.41	1	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	2.41	1	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
alsterpaullone alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.	2.41	1	0	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
quercetin [no description available]	2.37	2	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
genistein [no description available]	2.41	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
pachypodol pachypodol: new flavonoid isolated from Pachypodanthium confine; from Chinese herb Agastache folium; structure. pachypodol : A trimethoxyflavone that is quercetin in which the hydroxy groups at position 3, 7 and 3' are replaced by methoxy groups. It has been isolated from Combretum quadrangulare and Euodia elleryana.	2.37	2	0	dihydroxyflavone; trimethoxyflavone	antiemetic; plant metabolite
rottlerin rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.	2.41	1	0	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite
brefeldin a [no description available]	1.99	1	0	macrolide antibiotic	Penicillium metabolite
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	2.41	1	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide [no description available]	2.41	1	0	pyrimidines
bosutinib 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile: a Src kinase inhibitor; structure in first source	2.41	1	0	aminoquinoline; aromatic ether; dichlorobenzene; N-methylpiperazine; nitrile; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
su 11248 [no description available]	2.41	1	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
palbociclib [no description available]	2.41	1	0	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
thallium Thallium: A heavy, bluish white metal, atomic number 81, atomic weight [204.382; 204.385], symbol Tl.. thallium : A metallic element first identified and named from the brilliant green line in its flame spectrum (from Greek thetaalphalambdalambdaomicronsigma, a green shoot).	2.05	1	0	boron group element atom
gw-5074 [no description available]	2.47	2	0
enviradene [no description available]	2.89	4	0
ro 09-0410 Ro 09-0410: structure given in first source	8.98	4	0
rupintrivir rupintrivir: a rhinovirus 3C protease inhibitor	2.1	1	0
everolimus [no description available]	2.41	1	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
pd 184352 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source	2.41	1	0	aminobenzoic acid
bibx 1382bs BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001	2.41	1	0	substituted aniline
vacuolin-1 vacuolin-1: inhibits Ca2-dependent lysosomal exocytosis	2.41	1	0
pd 0325901 mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).	2.41	1	0	difluorobenzene; hydroxamic acid ester; monofluorobenzenes; organoiodine compound; propane-1,2-diols; secondary amino compound	antineoplastic agent; EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	2.41	1	0	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
tofacitinib tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.	2.41	1	0	N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound	antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
osu 03012 OSU 03012: a PDK-1 inhibitor; structure in first source	2.41	1	0	antibiotic antifungal drug; aromatic amide; glycine derivative; organofluorine compound; phenanthrenes; pyrazoles	antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
bx795 BX795: structure in first source	2.41	1	0	ureas
azd 6244 AZD 6244: a MEK inhibitor	2.41	1	0	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
a 443654 A 443654: an Akt kinase inhibitor; structure in first source	2.41	1	0	indoles
apilimod [no description available]	2.41	1	0
pik 75 PIK 75: structure in first source	2.41	1	0
saracatinib [no description available]	2.41	1	0	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	2.58	2	0
regorafenib [no description available]	2.41	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor
bi 2536 [no description available]	2.41	1	0
crizotinib Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)	2.41	1	0	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
trametinib [no description available]	2.41	1	0	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pha 767491 PHA 767491: a Cdc7 inhibitor; structure in first source	2.41	1	0	pyrrolopyridine
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	2.41	1	0	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide [no description available]	2.41	1	0	organochlorine compound
hbbpc [no description available]	2.41	2	0
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	1.97	1	0	1,2-diacyl-sn-glycero-3-phosphocholine
azd8330 [no description available]	2.41	1	0	pyridinecarboxamide
fedratinib fedratinib: a selective small-molecule inhibitor of JAK2	2.41	1	0	sulfonamide
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene: has antineoplastic activity; also inhibits Fms-like tyrosine kinase-3; structure in first source	2.41	1	0
phosphatidylinositol 4-phosphate phosphatidylinositol 4-phosphate : A phosphatidylinositol monophosphate carrying the phosphate group at the 4-position.	2.07	1	0
pci 32765 ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.	2.41	1	0	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
mk 2206 MK 2206: a protein kinase inhibitor and antineoplastic agent	2.41	1	0	organic heterotricyclic compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide: a Janus kinase 1 and Janus kinase 2 inhibitor; structure in first source. momelotinib : A benzamide obtained by formal condensation of the carboxy group of 4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzoic acid with the primary amino group of aminoacetonitrile. It is an ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 nM and 18 nM, respectively. Used for the treatment of patients with intermediate- or high-risk myelofibrosis.	2.41	1	0	aminopyrimidine; benzamides; morpholines; nitrile; secondary amino compound; tertiary amino compound	anti-anaemic agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
incb-018424 [no description available]	2.41	1	0	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
fit-039 FIT-039: CDK9 inhibitor; structure in first source	2.41	1	0
azd2014 vistusertib: potent and selective dual mTORC1 and mTORC2 inhibitor; structure in first source	2.41	1	0
bay 869766 [no description available]	2.41	1	0
baricitinib [no description available]	2.41	1	0	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent
piperidines Piperidines: A family of hexahydropyridines.	2.52	2	0
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide: a protein kinase inhibitor; structure in first source	2.41	1	0
ly2784544 [no description available]	2.41	1	0	pyridazines
sb 1518 [no description available]	2.41	1	0
dinaciclib [no description available]	2.41	1	0	pyrazolopyrimidine
gilteritinib gilteritinib: an FLT3/AXL protein tyrosine kinase inhibitor. gilteritinib : A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation.	2.41	1	0	aromatic amine; monomethoxybenzene; N-methylpiperazine; oxanes; piperidines; primary carboxamide; pyrazines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
glpg0634 [no description available]	2.41	1	0
delgocitinib delgocitinib: a Janus kinase inhibitor. delgocitinib : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a (3S,4R)-1-(cyanoacetyl)-3-methyl-1,6-diazaspiro[3.4]octan-6-yl group at position 4. It is a pan-Janus kinase (JAK) inhibitor and is approved for treatment of atopic dermatitis (AD) in Japan.	2.41	1	0	azaspiro compound; N-acylazetidine; nitrile; pyrrolopyrimidine; tertiary amino compound; tertiary carboxamide	anti-inflammatory drug; antipsoriatic; antiseborrheic; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
incb039110 INCB039110: a JAK1 inhibitor; structure in first source	2.41	1	0
vx-970 berzosertib: an ATR kinase inhibitor	2.41	1	0	sulfonamide
ldc4297 LDC4297: a CDK7 inhibitor with antineoplastic activity; structure in first source. LDC4297 : A pyrazolotriazine that is pyrazolo[1,5-a][1,3,5]triazine substituted by a piperidin-3-yloxy group, [2-(1H-pyrazol-1-yl)benzyl]nitrilo group and an isopropyl group at positions 2, 4 and 8 respectively. It is a potent and selective CDK7 inhibitor and exhibits antiviral activity.	2.41	1	0	aromatic ether; piperidines; pyrazoles; pyrazolotriazine; secondary amino compound	antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
at 9283 [no description available]	2.41	1	0
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	4.45	1	1	2-aminopurines; oxopurine	antimetabolite; antiviral drug
guanine [no description available]	2.13	1	0	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
ag-879 AG-879: structure given in first source	2.41	1	0
hesperadin [no description available]	2.41	1	0

Condition	Relationship Strength	Studies	Trials
Enterovirus Infections Diseases caused by ENTEROVIRUS.	4.99	6	0
2019 Novel Coronavirus Disease [description not available]	2.41	1	0
Viral Diseases [description not available]	4.72	2	1
Virus Diseases A general term for diseases caused by viruses.	4.72	2	1
Autoimmune Diabetes [description not available]	2.25	1	0
Coxsackie Virus Infections [description not available]	2.7	3	0
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	2.25	1	0
Catarrh Inflammation of a mucous membrane with increased flow of mucous in humans or animals. Catarrh is used mostly in a historical context.	9.16	11	5
Common Cold A catarrhal disorder of the upper respiratory tract, which may be viral or a mixed infection. It generally involves a runny nose, nasal congestion, and sneezing.	9.16	11	5
Foot and Mouth Disease [description not available]	2.1	1	0
Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)	2.13	1	0
Encephalitis, Polio [description not available]	3.32	2	0
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	3.32	2	0
Cerebrospinal Fluid Rhinorrhea Discharge of cerebrospinal fluid through the nose. Common etiologies include trauma, neoplasms, and prior surgery, although the condition may occur spontaneously. (Otolaryngol Head Neck Surg 1997 Apr;116(4):442-9)	3.34	1	1
Conjunctivitis, Acute Hemorrhagic A highly contagious disease characterized by subconjunctival hemorrhage, sudden swelling of the eyelids and congestion, redness, and pain in the eye. Epidemic conjunctivitis caused by Enterovirus 70 (EV-70) was first described in Africa in 1969. It is caused also by Coxsackievirus A24 variant (CA24v). Epidemics by this organism have appeared most frequently in Asia.	1.98	1	0
Infections, Picornaviridae [description not available]	3.77	2	0
Grippe [description not available]	4.27	1	1
Infections, Respiratory [description not available]	4.27	1	1
Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.	4.27	1	1
Pneumonia, Viral Inflammation of the lung parenchyma that is caused by a viral infection.	4.27	1	1
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	4.27	1	1
Echo Virus Infections [description not available]	2.88	1	0

viroxime

Cross-References

Synonyms (47)

Research Excerpts

Overview

Effects

Toxicity

Bioavailability

Dosage Studied

Bioassays (134)

Research

Studies (61)

Study Types

viroxime

Cross-References

Synonyms (47)

Research Excerpts

Overview

Effects

Toxicity

Bioavailability

Dosage Studied

Bioassays (134)

Research

Studies (61)

Study Types

Related Drugs (124)

Related Conditions (22)